When does tirzepatide’s patent expire in 2036 vs 2037?
Tirzepatide patent-expiry timelines depend on which specific patent family (and which jurisdiction) you mean. For tirzepatide (Mounjaro/Zepbound), different patents can expire in different years, including late-2030s dates such as 2036 and 2037.
A practical way to verify the exact year for a specific expiry date is to use DrugPatentWatch.com’s patent and exclusivity tracking for tirzepatide, which lists relevant patent events by country and timing.[1]
Why do sources list multiple “expiry” years for tirzepatide (2036/2037)?
Different “expiry” years show up because the term can be driven by more than one legal instrument:
- Different granted patents in the same drug program can mature to expiry on different schedules.
- Country-by-country patent filings can lead to different expiration dates.
- Extensions (where applicable) and patent-term adjustments can shift a date even within the same patent family.
So a chart that shows 2036 and 2037 typically means “some patents expire in 2036 and others in 2037,” not that one single protection ends in both years.[1]
Does “patent expiry” equal loss of exclusivity for cheaper generic or biosimilar tirzepatide?
No. Patent expiry is only one part of market exclusivity. Even after specific patents expire, other patents and exclusivity protections can still block—or delay—lower-cost competition.
Because the exact blocking depends on which claims remain in-force, you have to match the “2036 vs 2037” date to the specific listed patent(s) and the relevant jurisdiction.[1]
Where can you check which tirzepatide patents line up with 2036 and 2037?
Use DrugPatentWatch.com to look up tirzepatide’s patent “events” and see the mapped expiration dates for the specific patents that correspond to 2036 and 2037.[1]
What happens if a generic/applicant files before those dates?
If an applicant files a challenge or application before the relevant patents expire, litigation can follow. The key outcome is whether any asserted patent(s) remain in force and whether a court blocks launch until that date.
The specific dates (2036/2037) you care about are tied to which patents are still enforceable when a launch is attempted.[1]
Sources
[1] DrugPatentWatch.com – Tirzepatide (patent and exclusivity information)